Urgent Management of High‑Risk NSTEMI with Markedly Elevated Troponin

Immediate Medical Therapy

Initiate dual antiplatelet therapy (aspirin + P2Y12 inhibitor), anticoagulation, and urgent coronary angiography within hours for patients meeting high‑risk NSTE‑ACS criteria with markedly elevated troponin. ACC/AHA guideline – Class I, Level A. 1
Begin aspirin 75–150 mg immediately and continue indefinitely. ESC guideline – Class I, Level A. 3

Give ticagrelor 180 mg loading dose as the preferred P2Y12 inhibitor in ACS. ACC/AHA guideline – Class I, Level A. 2
Use prasugrel 60 mg loading dose when proceeding to PCI and no contraindications exist. ACC/AHA guideline – Class I, Level A. 6
Clopidogrel 300–600 mg loading is acceptable but less preferred in high‑risk patients. ESC guideline – Class IIa, Level B. 3

Start low‑molecular‑weight heparin (LMWH) or unfractionated heparin and continue through the time of angiography. ESC guideline – Class I, Level A. 3

Administer a β‑blocker unless contraindicated. ESC guideline – Class I, Level A. 3
Provide oral or intravenous nitrates if chest pain persists or recurs. ESC guideline – Class I, Level A. 3
Initiate high‑intensity statin therapy at presentation. ESC guideline – Class I, Level A. 5

Markedly elevated troponin (e.g., 3600 ng/L) is a high‑risk feature that mandates an early invasive strategy. ESC guideline – Class I, Level A. 3
Other high‑risk criteria include recurrent/persistent ischemia, hemodynamic instability, major arrhythmias, and diabetes mellitus. ESC guideline – Class I, Level A. 7
Perform coronary angiography within 4–24 hours for high‑risk NSTEMI patients. ACC/AHA guideline – Class I, Level A. 1
Reserve immediate angiography (≤2 hours) for severe ongoing ischemia, hemodynamic instability, life‑threatening arrhythmias, or cardiogenic shock. ACC/AHA & ESC guidelines – Class I, Level A. 1
Early angiography (≤24 hours) is appropriate for hemodynamically stable patients with significantly elevated troponin. ACC/AHA guideline – Class I, Level A. 1
Do not delay invasive evaluation with stress testing in high‑risk presentations. ACC/AHA guideline – Class I, Level A. 1

Obtain transthoracic echocardiography to assess left‑ventricular function and regional wall‑motion abnormalities. ESC guideline – Class I, Level A. 3
Maintain continuous ECG monitoring for at least 24 hours or until PCI is performed. ESC guideline – Class I, Level A. 10
Repeat a 12‑lead ECG if recurrent chest pain occurs. ESC guideline – Class I, Level A. 3
Monitor for hemodynamic instability (hypotension, pulmonary edema) and arrhythmias throughout the initial period. ESC guideline – Class I, Level A. 10

Consider GP IIb/IIIa inhibitors in very high‑risk patients undergoing PCI; they may be given upstream or at the time of PCI based on bleeding risk. ACC/AHA & ESC guidelines – Class IIa, Level B. 6
Bivalirudin is an acceptable alternative to unfractionated heparin plus GP IIb/IIIa inhibitors during PCI. ESC guideline – Class IIa, Level B. 10
Repeat coronary angiography is indicated even after a prior normal study because coronary disease can progress. ACC/AHA & ESC guidelines – Class I, Level A. 5

Do not postpone angiography solely because of a previous normal catheterization; disease progression and alternative diagnoses (e.g., SCAD) must be evaluated. ACC/AHA guideline – Class I, Level A. 1
Do not adopt a conservative strategy with stress testing first in high‑risk NSTEMI; elevated troponin mandates invasive assessment. ACC/AHA & ESC guidelines – Class I, Level A. 5
Do not withhold dual antiplatelet therapy while awaiting angiography in high‑risk patients. ACC/AHA guideline – Class I, Level A. 1
In women presenting with ACS—especially when prior angiography was normal—consider spontaneous coronary artery dissection (SCAD) as a potential etiology. ESC guideline – Class IIa, Level B. 8